These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33450317)

  • 1. Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages.
    Je H; Nam GH; Kim GB; Kim W; Kim SR; Kim IS; Lee EJ
    J Control Release; 2021 Mar; 331():7-18. PubMed ID: 33450317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designed trimer-mimetic TNF superfamily ligands on self-assembling nanocages.
    Kih M; Lee EJ; Lee NK; Kim YK; Lee KE; Jeong C; Yang Y; Kim DH; Kim IS
    Biomaterials; 2018 Oct; 180():67-77. PubMed ID: 30025246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
    J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.
    Cingöz A; Ozyerli-Goknar E; Morova T; Seker-Polat F; Esai Selvan M; Gümüş ZH; Bhere D; Shah K; Solaroglu I; Bagci-Onder T
    Oncogene; 2021 May; 40(18):3201-3216. PubMed ID: 33767436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression.
    James MA; Seibel WL; Kupert E; Hu XX; Potharla VY; Anderson MW
    Anticancer Drugs; 2015 Jun; 26(5):518-30. PubMed ID: 25646742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells.
    Komdeur R; Meijer C; Van Zweeden M; De Jong S; Wesseling J; Hoekstra HJ; van der Graaf WT
    Int J Oncol; 2004 Sep; 25(3):677-84. PubMed ID: 15289869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
    Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
    Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
    Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
    Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
    Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
    Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation.
    Horinaka M; Yoshida T; Nakata S; Shiraishi T; Tomosugi M; Yoshikawa S; Wakada M; Sakai T
    Cancer Sci; 2012 Feb; 103(2):282-7. PubMed ID: 22077238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.
    Jiang HH; Kim TH; Lee S; Chen X; Youn YS; Lee KC
    Biomaterials; 2011 Nov; 32(33):8529-37. PubMed ID: 21855130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes.
    Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X
    J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.
    Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X
    Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1.
    Baritaki S; Huerta-Yepez S; Sakai T; Spandidos DA; Bonavida B
    Mol Cancer Ther; 2007 Apr; 6(4):1387-99. PubMed ID: 17431117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5.
    Kim H; Kim EH; Eom YW; Kim WH; Kwon TK; Lee SJ; Choi KS
    Cancer Res; 2006 Feb; 66(3):1740-50. PubMed ID: 16452234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAIL therapy and prospective developments for cancer treatment.
    Thapa B; Kc R; Uludağ H
    J Control Release; 2020 Oct; 326():335-349. PubMed ID: 32682900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.